Aureka Biotechnologies

Aureka Biotechnologies is a biotech company that has developed an AI-powered platform for protein engineering and immunotherapeutic discovery. The company's platform integrates digital biology, artificial intelligence, and high-throughput, single-cell-based functional screening to accelerate the design of next-generation biologic and protein therapeutics.

Aureka's business model is centered around co-discovery partnerships with established pharmaceutical and biotech companies. Through these collaborations, the company applies its technology to design novel antibody therapeutics for challenging targets. This approach has demonstrated success and has led to the establishment of multiple partnerships. The company serves clients in the pharmaceutical and biotechnology sectors that are looking to enhance their therapeutic discovery and development pipelines.

Aureka has developed a proprietary GPT-like large language model (LLM) for protein design, which is trained on its own protein/protein co-evolution data. This, combined with high-throughput parallel evolution experiments, allows for the rapid generation and screening of a diverse and focused library of potential therapeutics. The company has recently secured $10 million in seed funding to further advance its platform and expand its operations.

Keywords: protein engineering, immunotherapeutics, AI-powered drug discovery, antibody therapeutics, high-throughput screening, digital biology, large language models, co-discovery partnerships, biologic therapeutics, single-cell analysis